Ligand Pharmaceuticals (LGND) EBT (2010 - 2026)

Ligand Pharmaceuticals has disclosed EBT across 17 years of filings, most recently posting -$24.3 million for Q1 2026.

• EBT for Q1 2026 came in at -$24.3 million, up 51.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $184.9 million (up 214.76% YoY), and the FY2025 annual result was $159.0 million, up 6212.95% from the prior year.
• EBT came in at -$24.3 million for Q1 2026 at Ligand Pharmaceuticals, down from $56.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of $141.1 million in Q3 2025 to a low of -$65.4 million in Q2 2024.
• The 5-year median for EBT is $8.7 million (2022), against an average of $13.9 million.
• Across the five-year window, EBT slumped 2162.13% in 2024 and surged 2326.49% in 2025, its largest moves.
• Ligand Pharmaceuticals' EBT stood at $24.1 million in 2022, then decreased by 29.18% to $17.1 million in 2023, then slumped by 329.28% to -$39.2 million in 2024, then soared by 244.85% to $56.8 million in 2025, then slumped by 142.72% to -$24.3 million in 2026.
• The last three EBT figures came in at -$24.3 million (Q1 2026), $56.8 million (Q4 2025), and $141.1 million (Q3 2025), per Business Quant data.